1. Home
  2. GNPX vs MTEX Comparison

GNPX vs MTEX Comparison

Compare GNPX & MTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.58

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Logo Mannatech Incorporated

MTEX

Mannatech Incorporated

HOLD

Current Price

$5.42

Market Cap

10.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
MTEX
Founded
2009
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
10.9M
IPO Year
2017
1998

Fundamental Metrics

Financial Performance
Metric
GNPX
MTEX
Price
$0.58
$5.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
373.7K
13.1K
Earning Date
05-11-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.49
Revenue
N/A
$108,038,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$11.06
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$3.80
52 Week High
$12.97
$12.45

Technical Indicators

Market Signals
Indicator
GNPX
MTEX
Relative Strength Index (RSI) 36.89 51.20
Support Level $0.17 $4.47
Resistance Level $2.12 $5.95
Average True Range (ATR) 0.06 0.39
MACD -0.00 -0.02
Stochastic Oscillator 42.85 37.04

Price Performance

Historical Comparison
GNPX
MTEX

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About MTEX Mannatech Incorporated

Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.

Share on Social Networks: